Cargando…

Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway

Background: The anti-inflammatory and antioxidant capacity of carnosine (CAR) has been investigated in autoimmune diseases. The aim of this study was to evaluate the potential protective effects of oral CAR supplements to ameliorate type 2 diabetes mellitus (T2DM)-induced osteoarthritis (OA) in rats...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yue, Wang, Yang, Kong, Yawei, Zhang, Xiaoning, Zhang, He, Gang, Yi, Bai, Lunhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997783/
https://www.ncbi.nlm.nih.gov/pubmed/29928231
http://dx.doi.org/10.3389/fphar.2018.00598
_version_ 1783331108175216640
author Yang, Yue
Wang, Yang
Kong, Yawei
Zhang, Xiaoning
Zhang, He
Gang, Yi
Bai, Lunhao
author_facet Yang, Yue
Wang, Yang
Kong, Yawei
Zhang, Xiaoning
Zhang, He
Gang, Yi
Bai, Lunhao
author_sort Yang, Yue
collection PubMed
description Background: The anti-inflammatory and antioxidant capacity of carnosine (CAR) has been investigated in autoimmune diseases. The aim of this study was to evaluate the potential protective effects of oral CAR supplements to ameliorate type 2 diabetes mellitus (T2DM)-induced osteoarthritis (OA) in rats and its mechanism. Methods: Seventy male Sprague–Dawley rats were randomly divided into the control group (CG, n = 10) and the T2DM group (n = 60). A rat model of T2DM was established using a high fat diet and streptozotocin (30 mg/kg, i.p.). The 41 rats that developed T2DM were chosen and randomly divided into four groups: T2DM-induced OA group (OAG, n = 11), and the T2DM-induced OA with low, moderate, and high-doses of CAR for 8 weeks group (CAR-L, CAR-M, and CAR-H, n = 10). After 13 weeks, all rats were evaluated by enzyme-linked immunosorbent assay (ELISA), histology, immunohistochemistry, and western blotting. Fibroblast-like synoviocytes (FLSs) were obtained from the knee joints of all rats. The effects of CAR on the inflammatory response in interleukin (IL)-1β-stimulated FLSs under a high glucose environment were evaluated by real-time quantitative polymerase chain reaction, western blotting, flow cytometry, and immunofluorescence. Results: The results of ELISA (IL-1β and tumor necrosis factor-α), the histological evaluation (Mankin and OARSI score), western blotting [COL2A1, matrix metalloproteinase (MMP)-3, MMP-13, IL-1β, and nuclear factor-kappaB (NF-κB) p65], and immunohistochemistry (COL2A1, MMP-3, and MMP-13) indicated that oral CAR attenuated the development of T2DM-induced OA and suppressed the inflammatory response. Moreover, CAR alleviated MMP-3 and MMP-13 expression levels by decreasing reactive oxygen species content and suppressing nuclear translocation of NF-κB p65 on IL-1β-induced FLSs in a high glucose environment. Conclusion: These findings indicate that oral CAR had chondroprotective effects on T2DM-induced OA through the reactive oxygen species (ROS)/NF-κB pathway.
format Online
Article
Text
id pubmed-5997783
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59977832018-06-20 Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway Yang, Yue Wang, Yang Kong, Yawei Zhang, Xiaoning Zhang, He Gang, Yi Bai, Lunhao Front Pharmacol Pharmacology Background: The anti-inflammatory and antioxidant capacity of carnosine (CAR) has been investigated in autoimmune diseases. The aim of this study was to evaluate the potential protective effects of oral CAR supplements to ameliorate type 2 diabetes mellitus (T2DM)-induced osteoarthritis (OA) in rats and its mechanism. Methods: Seventy male Sprague–Dawley rats were randomly divided into the control group (CG, n = 10) and the T2DM group (n = 60). A rat model of T2DM was established using a high fat diet and streptozotocin (30 mg/kg, i.p.). The 41 rats that developed T2DM were chosen and randomly divided into four groups: T2DM-induced OA group (OAG, n = 11), and the T2DM-induced OA with low, moderate, and high-doses of CAR for 8 weeks group (CAR-L, CAR-M, and CAR-H, n = 10). After 13 weeks, all rats were evaluated by enzyme-linked immunosorbent assay (ELISA), histology, immunohistochemistry, and western blotting. Fibroblast-like synoviocytes (FLSs) were obtained from the knee joints of all rats. The effects of CAR on the inflammatory response in interleukin (IL)-1β-stimulated FLSs under a high glucose environment were evaluated by real-time quantitative polymerase chain reaction, western blotting, flow cytometry, and immunofluorescence. Results: The results of ELISA (IL-1β and tumor necrosis factor-α), the histological evaluation (Mankin and OARSI score), western blotting [COL2A1, matrix metalloproteinase (MMP)-3, MMP-13, IL-1β, and nuclear factor-kappaB (NF-κB) p65], and immunohistochemistry (COL2A1, MMP-3, and MMP-13) indicated that oral CAR attenuated the development of T2DM-induced OA and suppressed the inflammatory response. Moreover, CAR alleviated MMP-3 and MMP-13 expression levels by decreasing reactive oxygen species content and suppressing nuclear translocation of NF-κB p65 on IL-1β-induced FLSs in a high glucose environment. Conclusion: These findings indicate that oral CAR had chondroprotective effects on T2DM-induced OA through the reactive oxygen species (ROS)/NF-κB pathway. Frontiers Media S.A. 2018-06-06 /pmc/articles/PMC5997783/ /pubmed/29928231 http://dx.doi.org/10.3389/fphar.2018.00598 Text en Copyright © 2018 Yang, Wang, Kong, Zhang, Zhang, Gang and Bai. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yang, Yue
Wang, Yang
Kong, Yawei
Zhang, Xiaoning
Zhang, He
Gang, Yi
Bai, Lunhao
Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway
title Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway
title_full Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway
title_fullStr Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway
title_full_unstemmed Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway
title_short Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-κB Pathway
title_sort carnosine prevents type 2 diabetes-induced osteoarthritis through the ros/nf-κb pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997783/
https://www.ncbi.nlm.nih.gov/pubmed/29928231
http://dx.doi.org/10.3389/fphar.2018.00598
work_keys_str_mv AT yangyue carnosinepreventstype2diabetesinducedosteoarthritisthroughtherosnfkbpathway
AT wangyang carnosinepreventstype2diabetesinducedosteoarthritisthroughtherosnfkbpathway
AT kongyawei carnosinepreventstype2diabetesinducedosteoarthritisthroughtherosnfkbpathway
AT zhangxiaoning carnosinepreventstype2diabetesinducedosteoarthritisthroughtherosnfkbpathway
AT zhanghe carnosinepreventstype2diabetesinducedosteoarthritisthroughtherosnfkbpathway
AT gangyi carnosinepreventstype2diabetesinducedosteoarthritisthroughtherosnfkbpathway
AT bailunhao carnosinepreventstype2diabetesinducedosteoarthritisthroughtherosnfkbpathway